The most significant complication of atrial fibrillation (AF) is thromboembolic stroke. Furthermore, the consequences of AF-related stroke tend to be more severe than those of other aetiologies. The need for safe, effective and convenient anticoagulation is clear. Warfarin is the current mainstay of treatment but its prescription and use remains sub-optimal, despite clear evidence and guidance to support its use. Many patients taking warfarin spend a significant amount of time subtherapeutically anticoagulated and the requirement for regular monitoring of warfarin's anticoagulant activity is both inconvenient and costly.
education
Atrial fibrillation (AF) is common and its prevalence is rising in parallel with increased life expectancy and an ageing population. Indeed, it is the most common sustained arrhythmia and one in four people over the age of 40 years will develop AF within their lifetime. 1 International data reflect a 0.9% population prevalence that rises to between 3% and 5% in those aged over 65 years and to more than 10% in octogenarians. 1, 2 Consistent data has been reported from the large Renfrew/Paisley cohort of over 15,000 Scottish people. 3 
AtriAl FibrillAtion And Stroke
Interventional techniques and, to an extent, pharmacotherapies have advanced to reduce symptoms directly associated with AF burden. However, the prevention of thromboembolic complications (primarily stroke) remains the over-riding priority. In the Framingham study, individuals with AF were at between four-and five-fold greater risk of stroke than those without. 4 This risk is further amplified in the context of additional risk factors including, but not limited to, diabetes mellitus, systemic hypertension or heart failure. In those aged 80-89 years, AF is responsible for just under 25% of all strokes. 4 Patients who suffer a stroke in the context of AF are more likely to die or suffer permanent disability. In an illuminating study performed prior to the advent of thrombolysis for the treatment of stroke, Lin et al. observed a 30-day mortality of 14% in patients with strokes occurring in the absence of AF, while 25% of those with AF-associated stroke were dead at 30 days. Furthermore, survivors of AF-related stroke had more recurrent cerebral ischaemic events and greater disability than those with non AF-associated stroke.
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VitAmin k AntAgoniStS
Since the 1950s, vitamin K antagonists (coumarin and its derivatives, primarily warfarin) have been the mainstay for use in oral anticoagulant therapy. They are highly Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation 1 NN Lang, 2 DT Connelly education effective in the reduction of ischaemic stroke in patients with AF, reducing the risk of stroke by 64% in comparison to placebo and by 37% when compared with antiplatelet therapy. 6 Further, the anticoagulant effect of warfarin is readily reversed by the administration of vitamin K and its anticoagulant effect is easily measured using the International Normalised Ratio (INR). Despite these favourable properties, warfarin has significant constraints that have caused problems with its use and limited its uptake even in groups at high risk for thromboembolic complications of AF.
Scoring systems such as the CHADS2 (congestive heart failure, hypertension, age, diabetes mellitus, stroke or transient ischaemic attack [TIA] or thromboembolism) and CHA2DS2-VASc (age 65-74, female, vascular disease) risk prediction models (Tables 1A and B and 2A and B) for thromboembolic risk in AF have been developed and validated. 7 They have been incorporated into major national 8, 9 and international 10,11 guidelines with the recommendation that patients at moderate or high risk of stroke should be anticoagulated ( Figure 1 ).
Warfarin is under-prescribed
Prescription and compliance with anticoagulation therapy remain disappointingly low. Notably, the Euro Heart Survey of AF patients revealed that only 67% of patients eligible for anticoagulation received this therapy and further concern remains that 'real world' prescribing is likely to be even lower. 12, 13 Reasons cited for the under-prescription of anticoagulants consistently include fear of precipitating bleeding. Although this can be a valid concern, it may also be overstated. Furthermore, the elderly are under-represented in anticoagulant treatment and are the very group who stand to benefit the most. 
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The HAS-BLED scoring tool for bleeding risk (Table 3) has also been incorporated into clinical guidelines to assist in anticoagulation decisions but it should be recognised that many of the risk factors for bleeding (including advancing age and previous stroke) are also strongly associated with thromboembolic stroke.
Maintaining therapeutic anticoagulation with warfarin is challenging
To achieve maximal therapeutic benefit for the prevention of ischaemic stroke it is important to achieve an INR of greater than two. However, exceeding an INR of 3.0 does not provide additional protection from ischaemic events but does result in a progressive increase in the likelihood of intra-cerebral haemorrhage. 15 Achieving a stable, therapeutic INR may be easier in some patients than others but warfarin dosing can be a challenge and is influenced by genetic and dietary factors as well as concomitant medication. Gladstone et al. illustrated both the under-use of anticoagulants in patients with AF and the concerning proportion of patients receiving anticoagulation but with sub-therapeutic INR. In patients known to have AF presenting with a stroke, 39% of patients were receiving anticoagulant treatment (all warfarin) but only a quarter of the anticoagulated patients had an INR within the therapeutic range. Although the group with AF who presented with a subsequent stroke or TIA were more likely to be receiving an anticoagulant (57%), less than a third of these patients had an INR within the therapeutic range at presentation. 16 Morgan and colleagues followed a group of over 6,000 Welsh patients with non-valvular AF. They demonstrated that in patients with AF at moderate or high risk for stroke, warfarin therapy is only effective at reducing the incidence of stroke if the target INR is achieved over 70% of the time. This is not often achieved in clinical practice. Furthermore, treatment with warfarin but with poor control (target INR achieved <30% of the time) appeared to be harmful.
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Therapeutic anticoagulation with warfarin is not immediate
There is frequently a delay in achieving a therapeutic INR after recognition of the need for anticoagulation in patients with AF. This stems from the pharmacokinetics of warfarin and the requirement for loading doses before a stable therapeutic INR is achieved. In some instances, local requirements for warfarin therapy to be initiated via a dedicated anticoagulation clinic contribute to further delay. These factors may conspire to provide further time for left atrial thrombus to develop in the fibrillating heart. Irrespective of the ease and timing of achieving a stable INR and dosing regimen, warfarin therapy always requires monitoring. Regardless of age, this is inconvenient for the patient and is cumbersome and expensive for healthcare systems.
Dabigatran
Rivaroxaban Apixaban The search for novel oral anticoagulants has been motivated by the drawbacks associated with warfarin. The pharmaceutical industry has been extremely competitive in the search for the ideal oral anticoagulant. Arguably, the perfect agent would have a rapid onset of action and predictable efficacy without the requirement for routine monitoring. It would protect from thromboembolism at least as well as warfarin and its haemorrhagic risk profile would be at least as safe, with the means to rapidly reverse its effect if required.
Ximelagatran was the first novel direct oral thrombin inhibitor to reach late phase trials and was granted approval for human use in several countries. It was hoped that this drug would replace warfarin but, after a considerable investment of time and finance, Ximelagatran was withdrawn in 2006 after significant hepatotoxic effects were observed.
Subsequent development proceeded and novel oral anticoagulants including dabigatran etexilate, rivaroxaban and apixaban are now available (Table 4) . Furthermore, they are now supported by randomised controlled trial data to support their use in the prevention of thromboembolism in patients with AF. [18] [19] [20] Although developed with the same goal, the mechanisms of action, pharmacokinetic and pharmacodynamic profiles vary sufficiently that they may allow, or perhaps even require, tailoring of the choice of therapy depending on specific patient characteristics and requirements. Indeed, randomised controlled data reinforce this point although no direct comparison of these new agents has been performed, nor is this likely to occur. The three major novel oral anticoagulants currently available will be reviewed individually. It should be considered, however, that warfarin may remain the most appropriate treatment for a large number of patients with AF, particularly those already maintained with a stable regime and with an infrequent, convenient INR monitoring system in place. Other novel oral anticaogulants, including edoxaban, darexaban and betrixaban continue in development but detailed discussion of these agents is outside the scope of this review.
Dabigatran etexilate
Unlike rivaroxaban and apixaban, which both act to inhibit the coagulation cascade via antagonism of factor X, dabigatran is a direct thrombin (factor II) inhibitor. Administered as a prodrug, dabigatran etexilate is metabolised by plasma and liver esterases to the active moiety, dabigatran. This is a competitive, reversible antagonist of thrombin that reaches its peak plasma activity between 30 minutes and two hours after oral administration. It has a half-life of between 12 and 17 hours with approximately 80% of the dabigatran excreted unaltered by the kidneys. Based upon this and other pharmacokinetic data, its effects have been examined using twice daily dosing regimens without coagulation monitoring. 21 It should be used with caution in patients receiving inhibitors of P-glycoprotein (quinidine, verapamil, amiodarone, clarithromycin). Although the combination of dronedarone and dabigtran should be avoided, the combination of amiodarone and dabigatran does not require dosage alteration. The co-administration of potent inducers of P-glycoprotein such as phenytoin, carbamazepine, St John's wort and rifampicin should be avoided ( Table 3 ). The use of dabigatran etexilate should be avoided in patients with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m 2 and in patients with severe liver disease.
The effect of dabigatran on thromboembolic complications in patients with AF was examined in the Randomised Evaluation of Long-term anticoagulant therapY (RE-LY) study. 18 This trial recruited 18,113 patients with AF and at least one other risk factor for stroke and randomly assigned patients to either dabigatran 110 mg twice daily (BD), dabigatran 150 mg BD or warfarin with a target INR of 2-3. Those patients receiving dabigatran were blinded to the treatment dose received but warfarin administration was open-labelled. The mean CHADS2 score for those recruited was 2.1 and the mean age of patients was 71.5 years. Those receiving warfarin had an INR within target range for 64% of the time. This result is similar to other major trials to include patients receiving warfarin but may be greater than achieved outside the clinical trial environment.
At a dose of 150 mg BD, dabigatran was associated with a significant reduction in ischaemic stroke or systemic embolism when compared with warfarin ( Guidance from the National Institute for Health and Clinical Excellence (NICE) is similar and highlights the importance of discussion between patient and healthcare provider regarding the differences between warfarin and dabigatran. Furthermore, they highlight that any decision to change from warfarin therapy to dabigatran should be made in the context of current INR stability.
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Rivaroxaban
Rivaroxaban is an oral factor Xa inhibitor. Factor Xa is pivotal in the coagulation cascade as it is responsible for the conversion of prothrombin to biologically potent thrombin. Rivaroxaban has an onset of action approximately three to four hours after administration with predictable pharmacokinetics. Furthermore, there is little variation in pharmacodynamics in relation to age, sex or body weight. It has a half-life of between five and nine hours in healthy individuals and between nine and 13 hours in the elderly. 25 It is administered as a once daily preparation. Around one-third of the drug is excreted via the kidneys while the remainder is metabolised by the liver. There are no reported food interactions with rivaroxaban and the propensity for drug interactions is said to be low. 26 It is, however, recommended that the administration of potent inhibitors of cytochrome P450 3A4 (such as antifungal agents, chloramphenicol, clarithromycin, protease inhibitors) and inhibitors of P-glycoprotein (listed above) should be avoided. Rivaroxaban may be cautiously co-administered with potent inducers of cytochrome P450 3A4 (such as phenytoin, carbamazepine, phenobarbital and St John's wort) as well as inducers of P-glycoprotein (also listed above). It should be avoided in severe liver disease with coagulopathy, given at a reduced dose when the eGFR lies between 15-49 mL/ min/1.73 m 2 , and avoided completely when renal function is worse than this.
Randomised controlled trial data to support the use of rivaroxaban in patients with AF comes from the Rivaroxaban once daily, Oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF). This study compared rivaroxaban 20 mg OD (15 mg OD in patients with eGFR 15-49 mL/min/1.73m 2 ) with warfarin (target INR 2-3) in 14,264 patients with nonvalvular AF and a CHADS2 score of at least two. This comprised a higher risk group than those studied in RE-LY, with a mean CHADS2 score of 3.47 and 55% of recruits having suffered a previous stroke, TIA or systemic embolism. Mean participant age was 73 years in both groups. Overall, warfarin therapy was less well controlled than in RE-LY with patients falling within target INR range for 58% of the time. Major bleeding and clinically relevant non-major bleeding rates were similar in both groups but, importantly, intracranial haemorrhage was less frequent in those receiving rivaroxaban (0.49% per year vs. 0.74% per year; HR 0.67 [CI 0.47-0.94]; p=0.019). 19 The SMC has considered the use of rivaroxaban in patients with non-valvular AF and one or more other risk factors for stroke. They approve the restricted use of rivaroxaban for patients who have poor INR control despite evidence that they are complying with a coumarin anticoagulant regimen. They also accept its use in patients who are allergic to or unable to tolerate coumarin anticoagulants. The SMC states that the once daily dosing schedule for rivaroxaban may confer some benefits to patients. Furthermore, its greater hepatic component to elimination may make it more suitable for patients with renal dysfunction. They recommend that patients with moderate to severe renal dysfunction receive a reduced dose of 15 mg once daily. 27 The National Institute for Health and Clinical Excellence has approved its use for the same patients either as a first choice anticoagulant or for those previously receiving warfarin. Again, they re-iterate the importance of an informed decision, particularly in the context of INR stability if a switch from warfarin is considered. 28 
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Apixaban
Like rivaroxaban, apixaban is a direct factor Xa inhibitor. Its onset of maximal action is between one and three hours after dosing and it has a half-life of around 12 hours in healthy volunteers. Therefore twice daily dosing is recommended. Approximately 25% of its excretion is via the kidneys and other than interaction with potent inhibitors of the cytochrome P450 3A4, there is minimal reported drug interaction and advice on co-prescription is similar to that for rivaroxaban. It is suggested that it can be used with caution in patients with eGFR 15-29 mL/min/1.73 m 2 and should be avoided if eGFR is less than 15 mL/min/1.73 m 2 . It should be noted, however that patients with eGFR <25mL/min/1.73 m 2 were not included in the phase III clinical trial of patients with AF. 29 Its use should be avoided in patients with severe liver disease or liver disease associated with coagulopathy. The standard recommended dose is 5 mg BD but this should be reduced to 2.5 mg BD in patients over the age of 80 years, those with a body weight of 60 kg and below, or serum creatinine ≥ 132 µmol/L.
The Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial provides the randomised controlled trial data to inform its use. 20 Published in 2011, after RE-LY and ROCKET-AF, this trial recruited 18,201 patients with AF and at least one risk factor for stroke. Subjects were randomised to receive either warfarin (target INR 2-3) or apixaban 5 mg BD (2.5 mg BD was given to patients recommended for dose reduction based upon the factors noted above). The patients recruited were marginally younger than those recruited to RE-LY and ROCKET-AF (mean age of patients was 70 years) and their stroke risk was lower than those in ROCKET-AF, but similar to RE-LY (mean CHADS2 score was 2.1); INR control was also similar to RE-LY, with patients spending an average of 62% of time within the target INR range.
After a median follow-up of 1.8 years, apixaban was shown to be superior to warfarin for the primary composite end-point of stroke or systemic embolism . 20 There were no unexpected side-effects reported in patients taking apixaban and fewer patients stopped taking it than warfarin during the trial period. 20 Apixaban has a variety of attractive properties, including less reliance upon renal excretion compared particularly with dabigatran, a good profile for tolerability as well as extremely encouraging clinical outcome data. Apixaban has had Food and Drug Administration (FDA) approval in the United States for the prevention of athromboembolic complications in patients with AF and has recently gained approval from both NICE and SMC for this indication.
CAutiouS optimiSm For the noVel orAl AntiCoAgulAntS
Costs
It is unclear whether the novel oral anticoagulants will eventually replace warfarin for thromboembolic stroke prevention in AF entirely. As with any new drug, particularly those for which there is a large eligible population, the financial cost of these agents has been a major concern for policy makers. While SMC and NICE have approved these three novel anticoagulants as outlined above and based upon a series of quality adjusted life year assessments, the true costs of these drugs remain to be seen. Unsurprisingly, the novel anticoagulants are more expensive than warfarin per se but there are also substantial costs inherent to current INR monitoring infrastructures. The potential for clinical benefit holds much greater emphasis for persuading policy changes rather than basing arguments simply on improved convenience for patients. As well as the obvious ethical element to this part of the argument, the large costs associated with caring for patients with either thromboembolic stroke or a haemorrhagic complication of anticoagulation need to be taken into account when making public health decisions.
Monitoring
Although some assays provide information, there is no standardised and routinely available method to give a quantification of the anticoagulant effect of the novel agents. 25 It can be crucial or, at the very least, useful to understand the degree of anticoagulation at times of emergency treatment for haemorrhage, for surgical procedures or for the assessment of potential anticoagulant overdose. Although the lack of requirement for regular routine anticoagulation monitoring can be seen as one of the major advantages of the novel oral anticoagulants over warfarin this may also prove to be a drawback for a subset of patients for whom achieving a stable INR while taking warfarin may, in fact, be noncompliant with medication. By switching these patients to a novel agent without the means to easily assess compliance we may, inadvertently, select a non-compliant population for (under-) treatment with novel agents.
Reversibility
Unlike the effects of warfarin that may be reversed by vitamin K, there is currently no simple antagonist to oppose the effects of the novel oral anticoagulants. This education remains a concern although the anticoagulant effect of the novel agents is shorter acting than that of warfarin. Haemodialysis may be used in case of dabigatran overdose 30 in view of its predominantly renal excretion but other measures are non-specific and include the administration of exogenous factor VII or fresh frozen plasma. The pharmaceutical industry understands that this deficiency is one of the major barriers to more widespread uptake of the novel agents. Clinical development of antagonists continues at pace.
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ConCluSionS
The risk of thromboembolism as a consequence of AF is well documented and the need for safe, effective and convenient anticoagulation is clear. Clinical risk prediction tools and their incorporation into major guidelines have clarified those who stand to gain the most from anticoagulation. However, warfarin prescription remains sub-optimal and, even when it is prescribed, many patients spend a significant amount of time with a subtherapeutic INR. The requirement for regular INR monitoring is both inconvenient and costly.
The advent of novel oral anticoagulants promises a more predictable and convenient means to achieve anticoagulation. In addition to potential superiority over warfarin for the prevention of stroke, they also appear to be associated with fewer haemorrhagic effects including intracranial bleeding. Warfarin remains tried and tested with a wealth of clinical experience behind its use. However, understanding the important background to the novel agents presents an opportunity to tailor anticoagulant treatment, for example in the context of renal dysfunction, bleeding risk and concomitant medication. The most satisfactory prescribing policy for these agents will depend on both financial considerations and an appreciation of the positive and negative aspects of the novel agents. However, the development of yet more preparations, and eventually antidotes, will allow treatment of a greater proportion of the large population with AF who are currently left overexposed to the devastating consequences of thromboembolic stroke.
reFerenCeS inVitAtion to Submit pAperS
We would like to extend an invitation to all readers of The Journal of the Royal College of Physicians of Edinburgh to contribute original material, especially to the clinical section. The JRCPE is a peer-reviewed journal with a circulation of 8,000. It is also available open access online. Its aim is to publish a range of clinical, educational and historical material of cross-specialty interest to the College's international membership.
The JRCPE is currently indexed in Medline, Embase, Google Scholar and the Directory of Open Access Journals. The editorial team is keen to continue to improve both the quality of content and its relevance to clinical practice for Fellows and Members. All papers are subject to peer review and our turnaround time for a decision averages only eight weeks.
We would be pleased to consider submissions based on original clinical research, including pilot studies. The JRCPE is a particularly good forum for research performed by junior doctors under consultant supervision. We would also consider clinical audits where the 'loop has been closed' and a demonstrable clinical benefit has resulted.
For further information about submissions, please visit: http://www.rcpe.ac.uk/journal/contributers.php or e-mail editorial@rcpe.ac.uk. Thank you for your interest in the College's journal.
The editorial team, The Journal of the Royal College of Physicians of Edinburgh
